The Effect of Bacille Calmette Guerin (BCG) Vaccination on Immune Responses in HIV-Exposed and Unexposed Infants
Primary Purpose
HIV Infections
Status
Unknown status
Phase
Phase 1
Locations
South Africa
Study Type
Interventional
Intervention
BCG delayed
Sponsored by
About this trial
This is an interventional prevention trial for HIV Infections focused on measuring BCG, HIV, Immune responses, Delayed vaccination, Infant morbidity, Nutritional status, Morbidity, Mortality
Eligibility Criteria
Inclusion Criteria: Maternal HIV status verified Study consent Uncomplicated singleton pregnancy with delivery planned at local health facility Resident in study area Exclusion Criteria: Active tuberculosis or tuberculosis contact in mother No consent Planning to move out of study area Not planning on delivering at local maternal obstetric unit Not planning on attending local baby clinic
Sites / Locations
- Desmond Tutu TB Centre
Outcomes
Primary Outcome Measures
BCG-induced cellular immune responses
Secondary Outcome Measures
BCG scarring
Serum antibody responses
Tuberculosis incidence
Full Information
NCT ID
NCT00331474
First Posted
May 30, 2006
Last Updated
February 13, 2009
Sponsor
University of Stellenbosch
Collaborators
Thrasher Research Fund
1. Study Identification
Unique Protocol Identification Number
NCT00331474
Brief Title
The Effect of Bacille Calmette Guerin (BCG) Vaccination on Immune Responses in HIV-Exposed and Unexposed Infants
Official Title
The Effect of BCG Vaccination on Immune Responses in HIV-Exposed and Unexposed Infants
Study Type
Interventional
2. Study Status
Record Verification Date
February 2009
Overall Recruitment Status
Unknown status
Study Start Date
May 2006 (undefined)
Primary Completion Date
December 2008 (Actual)
Study Completion Date
August 2009 (Anticipated)
3. Sponsor/Collaborators
Name of the Sponsor
University of Stellenbosch
Collaborators
Thrasher Research Fund
4. Oversight
5. Study Description
Brief Summary
Background:
Each year, more than half a million babies are infected with HIV by mother-to child transmission in developing countries. Many of these babies get sick and develop HIV disease (AIDS) at a very young age. Exposure to other infectious diseases may influence this early progression to AIDS. BCG is a live tuberculosis vaccine made from cow tuberculosis. It is routinely given at birth to most babies, also to babies born to HIV-positive mothers. BCG can cause disease (BCGosis) in HIV-infected babies. More importantly, BCG may also trigger immune responses in the body that lead to the spread of the HIV virus and early progression to AIDS.
Objective(s) and Hypothesis:
The researchers will investigate whether BCG causes progression of HIV by doing a clinical trial: babies born to HIV-positive mothers will be randomly allocated to get the BCG vaccine at birth or at 14 weeks of age. In these 2 groups of babies, the researchers will compare:
The percentage of babies who progress to HIV disease
Blood markers of HIV disease (the amount of virus and protective white blood cells in the body)
The body's immune response to BCG vaccine and other childhood vaccines
The percentage of children who develop BCG scarring, BCG vaccine complications and tuberculosis.
Potential Impact:
BCG is the most widely given vaccine worldwide and is routinely given to babies born to HIV-positive mothers in developing countries. Any effect that BCG has on HIV progression in babies will have a significant public health impact in settings with a high burden of HIV disease.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
HIV Infections
Keywords
BCG, HIV, Immune responses, Delayed vaccination, Infant morbidity, Nutritional status, Morbidity, Mortality
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 1, Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
180 (Anticipated)
8. Arms, Groups, and Interventions
Intervention Type
Biological
Intervention Name(s)
BCG delayed
Other Intervention Name(s)
early vs. delayed BCG
Intervention Description
early (birth) and delayed (14 weeks) intradermal BCG vaccination
Primary Outcome Measure Information:
Title
BCG-induced cellular immune responses
Time Frame
1 year
Secondary Outcome Measure Information:
Title
BCG scarring
Time Frame
18 months
Title
Serum antibody responses
Time Frame
52 weeks
Title
Tuberculosis incidence
Time Frame
1 year
10. Eligibility
Sex
All
Maximum Age & Unit of Time
48 Hours
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Maternal HIV status verified
Study consent
Uncomplicated singleton pregnancy with delivery planned at local health facility
Resident in study area
Exclusion Criteria:
Active tuberculosis or tuberculosis contact in mother
No consent
Planning to move out of study area
Not planning on delivering at local maternal obstetric unit
Not planning on attending local baby clinic
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Anneke C Hesseling, MD
Organizational Affiliation
Desmond Tutu TB Centre, Dept. Pediatrics and Child Health, Stellenbosch University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Desmond Tutu TB Centre
City
Cape Town
State/Province
Western Cape Province
ZIP/Postal Code
7505
Country
South Africa
12. IPD Sharing Statement
Learn more about this trial
The Effect of Bacille Calmette Guerin (BCG) Vaccination on Immune Responses in HIV-Exposed and Unexposed Infants
We'll reach out to this number within 24 hrs